Clinical Trial Update: Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating NovoTTF-100A (Tumor Treating Fields) for recurrent glioblastoma multiforme has completed, per the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• NovoTTF-100A (Tumor Treating Fields therapy)

Snippet

Sponsor: NovoCure Ltd. | Conditions: Recurrent Glioblastoma Multiforme | Phase 3 | Status: COMPLETED